NCT03090659
LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma No drug interventions treatment 1 / 2 active_not_recruiting NCT03674463
LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma No drug interventions treatment 1 unknown_status NCT03716856
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma treatment 1 unknown_status NCT03380039
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma treatment Not Available unknown_status NCT04649060
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma treatment 3 terminated NCT04762745
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma treatment 1 / 2 unknown_status NCT03710915
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma No drug interventions treatment 1 terminated NCT03683277
IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic treatment 2 terminated NCT00932698
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma treatment 1 completed NCT02223598
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies treatment 1 terminated NCT03029234
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma treatment 3 completed NCT02144038
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma treatment 1 completed NCT03559764
Study of BCMA CAR-T in Multiple Myeloma No drug interventions treatment 0 unknown_status NCT05530421
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma treatment 2 recruiting NCT03661554
BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma No drug interventions treatment 0 unknown_status NCT00664378
Efficacy Study of CYT997 in Multiple Myeloma treatment 2 terminated NCT04155749
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT06050512
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT03477643
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) No drug interventions Not Available Not Available completed NCT03755154
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) treatment 3 recruiting NCT05552976
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) treatment 3 recruiting NCT06604715
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 not_yet_recruiting NCT05455320
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment treatment 3 recruiting NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis No drug interventions treatment 1 recruiting NCT06208150
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide treatment 3 recruiting NCT06425991
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma treatment 1 recruiting NCT05927571
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) treatment 1 recruiting NCT06055075
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT06163040
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan Not Available Not Available recruiting NCT04798586
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma treatment 1 completed NCT05572515
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma treatment 3 recruiting NCT06574568
A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT02075021
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma treatment 1 / 2 terminated NCT03815383
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma No drug interventions treatment 1 unknown_status NCT01866293
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma treatment 1 / 2 completed NCT06500507
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma No drug interventions treatment 1 not_yet_recruiting NCT04626752
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 0 unknown_status NCT05052970
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM treatment 1 unknown_status NCT03464916
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients No drug interventions treatment 1 completed NCT06212596
Selinexor, Cyclophosphamide and Prednisone in Myeloma treatment 2 completed NCT06082596
Study of BEBT-908 in Subjects With Advanced Hematological Tumors No drug interventions treatment 1 completed NCT02099539
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 unknown_status NCT05757973
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma Not Available Not Available approved_for_marketing NCT03859427
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma treatment 3 completed NCT05920876
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT00708292
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. treatment 1 / 2 completed NCT05227144
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 active_not_recruiting NCT05913804
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 not_yet_recruiting NCT05647512
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases treatment 1 / 2 withdrawn NCT05918250
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) No drug interventions treatment 1 withdrawn NCT02834364
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) treatment 2 completed NCT00642954
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) treatment 1 completed NCT03512353
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers treatment 2 terminated NCT00478777
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma treatment 3 completed NCT05011097
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT02939183
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT03751293
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma No drug interventions treatment 1 unknown_status NCT05565807
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT03837509
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma treatment 1 / 2 terminated NCT02046915
Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide treatment 2 completed NCT02675452
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT04735575
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma No drug interventions treatment 1 / 2 recruiting NCT04939142
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) treatment 3 active_not_recruiting NCT04706936
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma treatment 1 recruiting NCT00545519
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma treatment 1 completed NCT01058434
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation treatment 2 completed NCT04191616
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet treatment 2 active_not_recruiting NCT06232096
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. No drug interventions treatment 1 / 2 recruiting NCT05463939
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients Not Available Not Available approved_for_marketing NCT05408026
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM treatment 1 / 2 withdrawn NCT06298266
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma No drug interventions treatment 0 not_yet_recruiting NCT04194931
Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma No drug interventions treatment 1 unknown_status NCT01670994
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 terminated NCT06375044
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT05503550
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma Not Available Not Available no_longer_available NCT04684108
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies No drug interventions treatment 1 active_not_recruiting NCT00773838
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) treatment 2 completed NCT04135963
A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal) No drug interventions Not Available Not Available completed NCT01897714
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients treatment 1 / 2 terminated NCT06285318
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials No drug interventions Not Available Not Available recruiting NCT02649790
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications treatment 1 / 2 active_not_recruiting NCT06351644
ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT06153251
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma treatment 1 recruiting NCT05893693
Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia No drug interventions treatment Not Available recruiting NCT04272775
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) treatment 1 terminated NCT06182696
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM treatment 1 / 2 recruiting NCT02831686
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma treatment 1 completed NCT05066022
A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma No drug interventions treatment Not Available unknown_status NCT04534322
Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma Not Available Not Available approved_for_marketing NCT04017130
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma other 1 terminated NCT03170882
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma treatment 2 completed NCT05297240
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. Not Available Not Available unknown_status NCT03433001
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone Not Available Not Available completed NCT05719701
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT01632150
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma treatment 2 completed NCT03836053
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma treatment 1 terminated NCT03715478
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex treatment 1 / 2 active_not_recruiting NCT05486975
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. No drug interventions treatment 0 recruiting NCT03903406
Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study Not Available Not Available unknown_status NCT02917941
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma treatment 2 completed NCT00882063
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma No drug interventions treatment 1 / 2 completed NCT04392648
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) other 1 withdrawn NCT03416374
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy treatment 4 completed NCT03242460
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) treatment 2 completed NCT03140943
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma treatment 2 unknown_status NCT04973605
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma treatment 1 / 2 recruiting NCT05160584
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT05801939
Cevostamab Following CAR T Cell Therapy for RRMM treatment 2 recruiting NCT05704049
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT05880043
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies No drug interventions treatment 1 / 2 recruiting NCT06049290
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT05332054
Long-Term Follow-up Study No drug interventions Not Available Not Available enrolling_by_invitation NCT05308654
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets treatment 1 recruiting NCT03196947
Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP No drug interventions treatment 1 / 2 terminated NCT05498545
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 not_yet_recruiting NCT06508983
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients treatment 3 recruiting NCT03309111
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma treatment 1 completed NCT05759793
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia No drug interventions treatment 1 recruiting NCT01794507
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy treatment 1 completed NCT02608515
A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease No drug interventions Not Available Not Available completed NCT03590652
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT04754100
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 completed NCT05722418
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma treatment 1 recruiting NCT04635735
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma treatment 1 / 2 terminated NCT05259839
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma treatment 1 recruiting NCT03489525
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 completed NCT01849848
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma No drug interventions treatment 2 completed NCT03450057
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment treatment 2 completed NCT06279026
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma No drug interventions treatment Not Available recruiting NCT05839626
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) No drug interventions treatment 1 / 2 recruiting NCT01794520
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT05286229
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan No drug interventions treatment 1 active_not_recruiting NCT05266768
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# No drug interventions treatment 1 unknown_status NCT05862012
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma treatment 1 recruiting NCT04309981
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. No drug interventions treatment 1 / 2 active_not_recruiting NCT03201250
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma treatment 1 / 2 terminated NCT05000450
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma treatment 1 / 2 terminated NCT03287908
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma treatment 1 terminated NCT04171843
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma treatment 1 terminated NCT05219721
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia No drug interventions treatment 1 unknown_status NCT06472479
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma treatment Not Available not_yet_recruiting NCT04998747
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) No drug interventions basic_science 1 withdrawn NCT05376345
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 recruiting NCT02755597
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy treatment 3 completed NCT03169361
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" Not Available Not Available completed NCT03318861
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma treatment 1 terminated NCT05270928
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# No drug interventions treatment 1 completed NCT05874193
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma treatment 2 not_yet_recruiting NCT05980507
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 withdrawn NCT06160609
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM treatment 1 / 2 terminated NCT04142619
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) No drug interventions treatment 1 terminated NCT04093596
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) treatment 1 active_not_recruiting NCT04896658
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT04601935
A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 active_not_recruiting NCT06369935
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. Not Available Not Available not_yet_recruiting NCT01102426
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma treatment 3 completed NCT05857982
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT06515262
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM No drug interventions treatment Not Available recruiting NCT05427812
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma treatment 1 / 2 recruiting NCT03473496
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma No drug interventions treatment Not Available terminated NCT04176380
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma treatment 2 unknown_status NCT03934684
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma treatment 4 active_not_recruiting NCT04505813
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma No drug interventions treatment 1 / 2 suspended NCT03732703
Myeloma-Developing Regimens Using Genomics (MyDRUG) treatment 1 / 2 unknown_status NCT00697684
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant treatment 1 completed NCT04150965
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT treatment 1 / 2 active_not_recruiting NCT04065425
Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT treatment 1 / 2 not_yet_recruiting NCT04776018
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) treatment 1 / 2 terminated NCT06103838
18F-Fluciclovine PET/CT in Multiple Myeloma treatment 2 recruiting NCT05338775
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma treatment 1 active_not_recruiting NCT05850234
A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT03445663
Study Evaluating AMG 424 in Subjects With Multiple Myeloma treatment 1 terminated NCT05461209
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma treatment 3 withdrawn